SCHEMBL18288604

SCHEMBL18288604

C[C@H]1COC(=O)[C@@H]1OC(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.45
BCHE P06276 3/20 0.44
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
GAA P10253 1/20 0.42
CHRNA7 P36544 2/20 0.41
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
HSD17B10 Q99714 2/20 0.41
MAPT P10636 1/20 0.41
TSHR P16473 2/20 0.41
APOBEC3A P31941 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40
GRM5 P41594 1/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18202479 0.83 MEN1 (0.42) TRPM8BCHEMEN1KMT2AGAA
SCHEMBL24772411 0.83 MEN1 (0.42) TRPM8BCHEMEN1KMT2AGAA
SCHEMBL9618911 0.83 BCHE (0.48) BCHEMEN1KMT2ACHRNA7HSD17B10
SCHEMBL23710673 0.83 MEN1 (0.42) TRPM8BCHEMEN1KMT2AGAA
SCHEMBL9921160 0.83 BCHE (0.48) BCHEMEN1KMT2ACHRNA7HSD17B10
SCHEMBL16140946 0.79 BCHE (0.50) BCHEMEN1KMT2AGAACHRNA7
SCHEMBL16311866 0.77 CHRM2 (0.56) BCHEMEN1KMT2AGAACHRNA7
SCHEMBL20067804 0.76 BCHE (0.40) TRPM8BCHEMEN1KMT2AGAA
SCHEMBL636837 0.75 LMNA (0.48) TRPM8MEN1KMT2AGAACHRNA7
SCHEMBL1751897 0.75 LMNA (0.48) TRPM8MEN1KMT2AGAACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159929-A1 MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF ALIGOS THERAPEUTICS, INC. 2023-05-25 US disclosed
US-20180105552-A1 NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS KU LEUVEN RESEARCH & DEVELOPMENT (BE) 2018-04-19 US disclosed
US-20160355805-A1 Double Stranded Oligonucleotide Compounds Comprising Positional Modifications QUARK PHARMACEUTICALS, INC. 2016-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159929-A1 MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) MOLECULES AND USES THEREOF SNRPA, SNRPA1, NSUN2 TRPM8 4381/4885BCHE 4825/4885MEN1 3394/4885
US-20180105552-A1 NOVEL ANTIVIRAL COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND THEIR USE FOR TREATING VIRAL INFECTIONS TYMP, MTAP, PNP TRPM8 3288/4885BCHE 1063/4885MEN1 1069/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.